Similar articles

• The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.

  McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. McGhan WF, et al. Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10. Value Health. 2009. PMID: 19744291
• Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.

  Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Johnson ML, et al. Value Health. 2009 Nov-Dec;12(8):1062-73. doi: 10.1111/j.1524-4733.2009.00602.x. Epub 2009 Sep 29. Value Health. 2009. PMID: 19793071
• Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.

  Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Cox E, et al. Value Health. 2009 Nov-Dec;12(8):1053-61. doi: 10.1111/j.1524-4733.2009.00601.x. Epub 2009 Sep 10. Value Health. 2009. PMID: 19744292
• Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.

  Manchikanti L, Falco FJ, Boswell MV, Hirsch JA. Manchikanti L, et al. Pain Physician. 2010 Jan-Feb;13(1):E23-54. Pain Physician. 2010. PMID: 20119474 Review.
• A review of covariate selection for non-experimental comparative effectiveness research.

  Sauer BC, Brookhart MA, Roy J, VanderWeele T. Sauer BC, et al. Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1139-45. doi: 10.1002/pds.3506. Epub 2013 Sep 5. Pharmacoepidemiol Drug Saf. 2013. PMID: 24006330 Free PMC article. Review.